Legend Biotech reported a Q1 loss of 3 cents per share, missing the expected 2 cents loss, and sales of $305.1 million, slightly below the $307 million forecast. Despite the miss, shares rose 1.3% to $28.63. Analysts reacted with mixed price target adjustments: RBC Capital raised its target to $64, Morgan Stanley lowered it to $48, and TD Cowen increased it to $29. CEO Ying Huang highlighted strong growth in their CARVYKTI product and improving margins, signaling progress toward profitability and pipeline expansion.
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
